Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Atrovent® - inhalets

Study type: Observational

Funder types: Industry

Identifiers

NCT02233881

244.2501

Details and patient eligibility

About

Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

Enrollment: 4,222 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of both gender older than 40 years, who suffer from Chronic Obstructive Pulmonary Disease
• Only patients who have not been treated with Atrovent® within the last year are to be considered for inclusion

Exclusion criteria

• Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® metered dose inhaler

Trial design

4,222 participants in 1 patient group

Chronic obstructive pulmonary disease patients

Treatment:

Drug: Atrovent® - inhalets